Have human studies found increased thyroid cancer?

The cohort and randomised evidence described has not produced the signal the rodent toxicology raised. That is not the same as demonstrated absence of risk.

Has the boxed warning been removed?

No. It remains in place, and removing labelling requires a positive regulatory case rather than accumulating null findings.

Research & Regulatory News

What the Human Studies Have Found

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Human evidence on thyroid cancer risk with GLP-1 receptor agonists includes a Scandinavian cohort study in the BMJ, an analysis of 13 obesity-associated cancers in JAMA Network Open, and a 2025 meta-analysis of randomised controlled trials.

Key facts

Pasternak 2024: BMJ, Scandinavian cohort (PMID 38683947)
Wang 2024: JAMA Netw Open, 13 cancers (PMID 38967919)
Silverii 2025: Diabetes Obes Metab, RCT meta-analysis (PMID 40437949)
Origin of concern: Rodent toxicology
Mechanistic context: Species difference in receptor expression
Boxed warning: Remains in place

Why cohort studies suit this question

Thyroid cancer is rare and develops over years. A randomised trial powered to detect a difference in its incidence would need to be impractically large and long. National registry cohorts provide the numbers and the follow-up that trials cannot, which is why the Scandinavian health registries are used for questions of this shape.

What the Scandinavian cohort offers

Pasternak and colleagues published on GLP-1 receptor agonist use and risk of thyroid cancer in the BMJ in April 2024. Scandinavian registries link prescribing, diagnoses and outcomes across whole populations with little loss to follow-up, which removes several biases that weaken cohort studies assembled from other sources.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What a broader cancer analysis adds

Wang and colleagues examined GLP-1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes in JAMA Network Open in July 2024. Looking across many cancer types simultaneously puts any single finding in context — and requires care, because examining thirteen outcomes raises the chance of one appearing notable by chance alone.

What a meta-analysis of trials contributes

Silverii and colleagues pooled randomised controlled trials in Diabetes, Obesity and Metabolism in 2025. Randomised data avoids confounding by indication — the problem that people prescribed a drug differ from those who are not. Its limitation is duration: pooling trials of a few years cannot address a cancer latency measured in decades.

Why the designs are complementary rather than competing

Trials are randomised but short. Cohorts are long but observational. Neither alone settles a rare, slow-developing outcome, and agreement between designs with different weaknesses is worth more than any single result. That convergence is the strongest form the evidence here can currently take.

How this sits against the warning

The boxed warning derives from rodent toxicology, and Waser and colleagues showed the receptor is not detected in normal human thyroid — a mechanistic reason the rodent finding might not extend. Human studies to date have not produced the signal the rodent data raised. None of that constitutes demonstrated absence of risk, and the warning remains on the labels.

What this does not concern

Research material. Every study described here examines licensed medicines prescribed and monitored clinically. Nothing supplied on this site is a GLP-1 receptor agonist or is described by any of this evidence.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Have human studies found increased thyroid cancer?: The cohort and randomised evidence described has not produced the signal the rodent toxicology raised. That is not the same as demonstrated absence of risk.
Why use registry cohorts rather than trials?: Thyroid cancer is rare and slow to develop. A trial powered to detect a difference in its incidence would be impractically large and long.
Has the boxed warning been removed?: No. It remains in place, and removing labelling requires a positive regulatory case rather than accumulating null findings.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum